PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32711417-0 2020 ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy. Platinum 121-129 glutathione S-transferase pi 1 Homo sapiens 18-23 32880833-0 2020 Genetic polymorphisms of GSTP1, XRCC1, XPC and ERCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer patients of Bangladesh. Platinum 88-96 glutathione S-transferase pi 1 Homo sapiens 25-30 32880833-6 2020 Although GSTP1 (rs1695) polymorphism might serve as prognostic factor regarding grade 3 or 4 neutropenia, a significant (p = 0.044) improvement in response to platinum-based chemotherapy was observed. Platinum 159-167 glutathione S-transferase pi 1 Homo sapiens 9-14 32880833-8 2020 XRCC1 (rs2228001) and GSTP1 (rs1695) polymorphisms might explain platinum-induced clinical outcomes in terms of both toxicity and therapeutic response variations among Bangladeshi advanced NSCLC patients. Platinum 65-73 glutathione S-transferase pi 1 Homo sapiens 22-27 32711417-3 2020 Methods: We conducted the study to investigate the association between polymorphisms of ERCC1, XRCC1 and GSTP1, which responsible for platinum"s metabolisms in Thai epithelial ovarian cancer patients. Platinum 134-142 glutathione S-transferase pi 1 Homo sapiens 105-110 32711417-9 2020 CONCLUSIONS: Genetic polymorphisms of ERCC1, and GSTP1 might be useful biomarkers for prediction of clinical benefit and toxicities of platinum-based chemotherapy in Thai epithelial ovarian cancer patients.
. Platinum 135-143 glutathione S-transferase pi 1 Homo sapiens 49-54 31602266-4 2019 24%, 46%, 40%, 5%, and 44% GC had a potentially platinum sensitive phenotype by SNP analyses of GSTP1, ERCC1 rs11615, ERCC1 rs3212986, ERCC2, and XRCC1, respectively. Platinum 48-56 glutathione S-transferase pi 1 Homo sapiens 96-101 30973677-0 2019 Association of GSTP1 and ERCC1 polymorphisms with toxicity in locally advanced head and neck cancer platinum-based chemoradiotherapy treatment. Platinum 100-108 glutathione S-transferase pi 1 Homo sapiens 15-20 30854066-0 2019 GSTP1 as a potential predictive factor for adverse events associated with platinum-based antitumor agent-induced peripheral neuropathy. Platinum 74-82 glutathione S-transferase pi 1 Homo sapiens 0-5 30854066-3 2019 In the present study, it was determined whether GSTP1 can predict adverse events associated with platinum-based antitumor agent-induced peripheral neuropathy among Japanese patients. Platinum 97-105 glutathione S-transferase pi 1 Homo sapiens 48-53 30238837-0 2018 Relationship between GSTP1 rs1695 gene polymorphism and myelosuppression induced by platinum-based drugs: a meta-analysis. Platinum 84-92 glutathione S-transferase pi 1 Homo sapiens 21-26 30238837-1 2018 Although many previous studies have reported the relationship between GSTP1 rs1695 gene polymorphism and myelosuppression induced by platinum-based drugs, the conclusions are not consistent. Platinum 133-141 glutathione S-transferase pi 1 Homo sapiens 70-75 30238837-2 2018 The aim of the study is to evaluate the association between granulocytopenia and thrombocytopenia induced by platinum-based drugs and GSTP1 rs1695 gene polymorphism by meta-analysis. Platinum 109-117 glutathione S-transferase pi 1 Homo sapiens 134-139 30238837-5 2018 GSTP1 rs1695 gene polymorphism showed a significant correlation with granulocytopenia induced by platinum-based drugs (dominant genetic model: OR=1.60, 95% CI=1.19. Platinum 97-105 glutathione S-transferase pi 1 Homo sapiens 0-5 30238837-11 2018 In conclusion, the GSTP1 rs1695 gene polymorphism is associated with granulocytopenia induced by platinum-based drugs. Platinum 97-105 glutathione S-transferase pi 1 Homo sapiens 19-24 30313031-3 2018 This study investigates the relationship between the expression levels of lung resistance protein (LRP) and placental glutathione S-transferase-P1 (GSTP1), the resistance of primary epithelial ovarian cancer (PEOC) to chemotherapy, and the prognosis of patients with platinum drug-resistant PEOC.Quantitative PCR (QT-PCR) was used to detect the mRNA level of the resistance genes LRP, GSTP1 in all tissue and cell lines.The expression levels of resistance gene (LRP, GSTP1) in PEOC were the highest, followed by borderline adenoma tissues, and the lowest levels found in benign tumor tissues, the difference of genes expression between different tissues was statistically significant; the difference between the expression rates and relative expression level of drug resistance genes was statistically significant in platinum sensitive group compare with the platinum resistant group. Platinum 817-825 glutathione S-transferase pi 1 Homo sapiens 118-146 30313031-3 2018 This study investigates the relationship between the expression levels of lung resistance protein (LRP) and placental glutathione S-transferase-P1 (GSTP1), the resistance of primary epithelial ovarian cancer (PEOC) to chemotherapy, and the prognosis of patients with platinum drug-resistant PEOC.Quantitative PCR (QT-PCR) was used to detect the mRNA level of the resistance genes LRP, GSTP1 in all tissue and cell lines.The expression levels of resistance gene (LRP, GSTP1) in PEOC were the highest, followed by borderline adenoma tissues, and the lowest levels found in benign tumor tissues, the difference of genes expression between different tissues was statistically significant; the difference between the expression rates and relative expression level of drug resistance genes was statistically significant in platinum sensitive group compare with the platinum resistant group. Platinum 267-275 glutathione S-transferase pi 1 Homo sapiens 118-146 30313031-3 2018 This study investigates the relationship between the expression levels of lung resistance protein (LRP) and placental glutathione S-transferase-P1 (GSTP1), the resistance of primary epithelial ovarian cancer (PEOC) to chemotherapy, and the prognosis of patients with platinum drug-resistant PEOC.Quantitative PCR (QT-PCR) was used to detect the mRNA level of the resistance genes LRP, GSTP1 in all tissue and cell lines.The expression levels of resistance gene (LRP, GSTP1) in PEOC were the highest, followed by borderline adenoma tissues, and the lowest levels found in benign tumor tissues, the difference of genes expression between different tissues was statistically significant; the difference between the expression rates and relative expression level of drug resistance genes was statistically significant in platinum sensitive group compare with the platinum resistant group. Platinum 267-275 glutathione S-transferase pi 1 Homo sapiens 148-153 30313031-3 2018 This study investigates the relationship between the expression levels of lung resistance protein (LRP) and placental glutathione S-transferase-P1 (GSTP1), the resistance of primary epithelial ovarian cancer (PEOC) to chemotherapy, and the prognosis of patients with platinum drug-resistant PEOC.Quantitative PCR (QT-PCR) was used to detect the mRNA level of the resistance genes LRP, GSTP1 in all tissue and cell lines.The expression levels of resistance gene (LRP, GSTP1) in PEOC were the highest, followed by borderline adenoma tissues, and the lowest levels found in benign tumor tissues, the difference of genes expression between different tissues was statistically significant; the difference between the expression rates and relative expression level of drug resistance genes was statistically significant in platinum sensitive group compare with the platinum resistant group. Platinum 817-825 glutathione S-transferase pi 1 Homo sapiens 148-153 30313031-3 2018 This study investigates the relationship between the expression levels of lung resistance protein (LRP) and placental glutathione S-transferase-P1 (GSTP1), the resistance of primary epithelial ovarian cancer (PEOC) to chemotherapy, and the prognosis of patients with platinum drug-resistant PEOC.Quantitative PCR (QT-PCR) was used to detect the mRNA level of the resistance genes LRP, GSTP1 in all tissue and cell lines.The expression levels of resistance gene (LRP, GSTP1) in PEOC were the highest, followed by borderline adenoma tissues, and the lowest levels found in benign tumor tissues, the difference of genes expression between different tissues was statistically significant; the difference between the expression rates and relative expression level of drug resistance genes was statistically significant in platinum sensitive group compare with the platinum resistant group. Platinum 817-825 glutathione S-transferase pi 1 Homo sapiens 118-146 30313031-3 2018 This study investigates the relationship between the expression levels of lung resistance protein (LRP) and placental glutathione S-transferase-P1 (GSTP1), the resistance of primary epithelial ovarian cancer (PEOC) to chemotherapy, and the prognosis of patients with platinum drug-resistant PEOC.Quantitative PCR (QT-PCR) was used to detect the mRNA level of the resistance genes LRP, GSTP1 in all tissue and cell lines.The expression levels of resistance gene (LRP, GSTP1) in PEOC were the highest, followed by borderline adenoma tissues, and the lowest levels found in benign tumor tissues, the difference of genes expression between different tissues was statistically significant; the difference between the expression rates and relative expression level of drug resistance genes was statistically significant in platinum sensitive group compare with the platinum resistant group. Platinum 817-825 glutathione S-transferase pi 1 Homo sapiens 148-153 28572675-1 2017 The influences of glutathione s-transferase P1, M1, and T1 variants on the efficacy of platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients were inconsistent in previous studies. Platinum 87-95 glutathione S-transferase pi 1 Homo sapiens 18-46 28572675-6 2017 Our meta-analysis suggested that the GSTP1 IIe105Val, GSTM1 and GSTT1 null variants might be predictive factors for the efficacy of platinum-based chemotherapy to NSCLC patients. Platinum 132-140 glutathione S-transferase pi 1 Homo sapiens 37-42 28572675-7 2017 The use of GSTP1 IIe105Val, GSTM1 and GSTT1 null polymorphisms as predictive factors of efficacy of personalized platinum-based chemotherapy to NSCLC patients requires further verification with multi-center, multi-ethnic and large-sample-size pharmacogenetic studies. Platinum 113-121 glutathione S-transferase pi 1 Homo sapiens 11-16 24765164-8 2014 In the present patient, the glutathione S-transferase P1 (GSTP1) gene polymorphism, which is involved in the detoxification of platinum drugs, was analyzed. Platinum 127-135 glutathione S-transferase pi 1 Homo sapiens 28-56 25010864-0 2014 Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines. Platinum 57-65 glutathione S-transferase pi 1 Homo sapiens 0-28 25010864-0 2014 Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines. Platinum 57-65 glutathione S-transferase pi 1 Homo sapiens 30-35 25010864-2 2014 Platinum drugs are metabolised by glutathione S-transferase P1 (GSTP1), which is abundantly, but variably expressed in ovarian tumours. Platinum 0-8 glutathione S-transferase pi 1 Homo sapiens 34-62 25010864-2 2014 Platinum drugs are metabolised by glutathione S-transferase P1 (GSTP1), which is abundantly, but variably expressed in ovarian tumours. Platinum 0-8 glutathione S-transferase pi 1 Homo sapiens 64-69 25010864-11 2014 Inter-tumour differences in GSTP1 expression may therefore influence response to platinum-based chemotherapy in ovarian cancer patients. Platinum 81-89 glutathione S-transferase pi 1 Homo sapiens 28-33 24729086-0 2014 The association between the GSTP1 A313G and GSTM1 null/present polymorphisms and the treatment response of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients: a meta-analysis. Platinum 111-119 glutathione S-transferase pi 1 Homo sapiens 28-33 24729086-1 2014 The relationship between the GSTP1 A313G and GSTM1 null/present polymorphisms and the treatment response (TR) of platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients have been extensively investigated by many studies, but the results were inconsistent and inconclusive. Platinum 113-121 glutathione S-transferase pi 1 Homo sapiens 29-34 28442702-7 2017 CONCLUSIONS Polymorphisms of GSTP1 rs1695 and ABCC2 rs717620 can be used to predict the outcomes of Uygur patients with advanced NSCLC who have received platinum-based chemotherapy. Platinum 153-161 glutathione S-transferase pi 1 Homo sapiens 29-34 27073511-1 2016 The effects of platinum-based drugs are controlled by genes that are involved in DNA detoxification, including glutathione S-transferase (GST)P1 and GSTM1, which have been associated with increased benefits in the chemotherapeutic treatment of patients with ovarian cancer. Platinum 15-23 glutathione S-transferase pi 1 Homo sapiens 138-144 24958519-0 2014 Genetic polymorphism of GSTP1 and ERCC1 correlated with response to platinum-based chemotherapy in non-small cell lung cancer. Platinum 68-76 glutathione S-transferase pi 1 Homo sapiens 24-29 24958519-1 2014 The study aims to investigate whether the glutathione S transferase P1 (GSTP1) and excision repair cross-complementing group 1 (ERCC1) polymorphism influence the response to treatment with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer. Platinum 189-197 glutathione S-transferase pi 1 Homo sapiens 42-70 24958519-1 2014 The study aims to investigate whether the glutathione S transferase P1 (GSTP1) and excision repair cross-complementing group 1 (ERCC1) polymorphism influence the response to treatment with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer. Platinum 189-197 glutathione S-transferase pi 1 Homo sapiens 72-77 24958519-16 2014 GSTP1 and ERCC1 polymorphism are correlated with response to platinum-based chemotherapy and have prognostic value for TTP. Platinum 61-69 glutathione S-transferase pi 1 Homo sapiens 0-5 24729086-11 2014 Our study suggested that the GSTP1 A313G and GSTM1 null/present polymorphisms could predict the treatment response of the platinum-based chemotherapy in NSCLC patients, especially in East-Asian patients. Platinum 122-130 glutathione S-transferase pi 1 Homo sapiens 29-34 24765164-8 2014 In the present patient, the glutathione S-transferase P1 (GSTP1) gene polymorphism, which is involved in the detoxification of platinum drugs, was analyzed. Platinum 127-135 glutathione S-transferase pi 1 Homo sapiens 58-63 22031394-8 2012 Patients who carried the homozygous mutant glutathione S-transferase pi 1(GSTP1) GG genotype were at considerable risk for severe platinum-associated polyneuropathy (18% vs 3% in wild-type vs heterozygous mutant patients, respectively; P = .01). Platinum 130-138 glutathione S-transferase pi 1 Homo sapiens 43-73 22031394-8 2012 Patients who carried the homozygous mutant glutathione S-transferase pi 1(GSTP1) GG genotype were at considerable risk for severe platinum-associated polyneuropathy (18% vs 3% in wild-type vs heterozygous mutant patients, respectively; P = .01). Platinum 130-138 glutathione S-transferase pi 1 Homo sapiens 74-79 21766492-3 2011 Polymorphisms within the GSTP1 may result in alterations in enzyme activity and change sensitivity to platinum-based chemotherapy. Platinum 102-110 glutathione S-transferase pi 1 Homo sapiens 25-30 23167352-8 2012 CONCLUSION: This study indicated that GSTP1 Ile105Val, XRCC1 Arg194Trp and XRCC1Arg399Gln genes have a role in modifying the effect of platinum-based chemotherapy for NSCLC patients in a Chinese population. Platinum 135-143 glutathione S-transferase pi 1 Homo sapiens 38-43 22009704-0 2011 Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. Platinum 76-84 glutathione S-transferase pi 1 Homo sapiens 25-30 22009704-2 2011 Genetic polymorphisms of GSTP1 and XRCC1 involved in glutathione metabolic and DNA repair pathways may explain inter individual differences in chemosensitivity and clinical outcome in NSCLC patients treated with platinum-based regimens. Platinum 212-220 glutathione S-transferase pi 1 Homo sapiens 25-30 22009704-7 2011 CONCLUSION: Genetic polymorphisms of GSTP1 and XRCC1 may be important predictive factors in platinum-treated patients with advanced NSCLC. Platinum 92-100 glutathione S-transferase pi 1 Homo sapiens 37-42 19396019-2 2009 Glutathione S-transferase-pi (GSTP1) belongs to a supergene family of detoxifying enzymes involved in the prevention of DNA damage and subsequent platinum resistance in numerous cancers. Platinum 146-154 glutathione S-transferase pi 1 Homo sapiens 30-35 19568750-2 2010 We hypothesize that genetic polymorphisms in metabolising enzymes gene GSTP1 (glutathione S-transferase P1), and MRP2 (multidrug resistance-associated protein 2) (ABCC2), which result in inter-individual differences in metabolism and drug disposition, may predict clinical response to platinum agents in advanced non-small cell lung cancer (NSCLC) patients. Platinum 285-293 glutathione S-transferase pi 1 Homo sapiens 71-76 19568750-2 2010 We hypothesize that genetic polymorphisms in metabolising enzymes gene GSTP1 (glutathione S-transferase P1), and MRP2 (multidrug resistance-associated protein 2) (ABCC2), which result in inter-individual differences in metabolism and drug disposition, may predict clinical response to platinum agents in advanced non-small cell lung cancer (NSCLC) patients. Platinum 285-293 glutathione S-transferase pi 1 Homo sapiens 78-106 19568750-7 2010 RESULTS: The C-->T change of MRP2 C-24T and the A-->G change of GSTP1 Ile105Val polymorphism significantly increased platinum-based chemotherapy response. Platinum 123-131 glutathione S-transferase pi 1 Homo sapiens 70-75 19922504-1 2010 Glutathione S-transferase P1 (GSTP1) participates in detoxification of potentially genotoxic compounds that may alter the efficacy and toxicity of platinum-based chemotherapy. Platinum 147-155 glutathione S-transferase pi 1 Homo sapiens 0-28 19922504-1 2010 Glutathione S-transferase P1 (GSTP1) participates in detoxification of potentially genotoxic compounds that may alter the efficacy and toxicity of platinum-based chemotherapy. Platinum 147-155 glutathione S-transferase pi 1 Homo sapiens 30-35 19661073-1 2009 Detoxification enzymes, especially glutathione S-transferase P1-1 (GSTP1-1), have been implicated in resistance to platinum-based chemotherapy. Platinum 115-123 glutathione S-transferase pi 1 Homo sapiens 67-74 18085999-1 2007 INTRODUCTION: Glutathione S-transferase P1 (GSTP1) and excision-repair cross-complementing repair deficiency group 2 protein (ERCC2 or XPD) may modulate the activity of platinum derivatives. Platinum 169-177 glutathione S-transferase pi 1 Homo sapiens 14-42 19362955-2 2009 We retrospectively assessed whether single nucleotide polymorphisms (SNP) of DNA-repair genes ERCC1, XPD, XRCC1 and glutathione S-transferase genes GSTP1, GSTT1 and GSTM1 predict overall survival (OS), response and toxicity in 119 non-small-cell lung cancer (NSCLC) patients treated with platinum-based regimens as first- or second-line chemotherapy. Platinum 288-296 glutathione S-transferase pi 1 Homo sapiens 148-153 18085999-1 2007 INTRODUCTION: Glutathione S-transferase P1 (GSTP1) and excision-repair cross-complementing repair deficiency group 2 protein (ERCC2 or XPD) may modulate the activity of platinum derivatives. Platinum 169-177 glutathione S-transferase pi 1 Homo sapiens 44-49 12914384-6 2003 XRCC1 (X-ray cross-complementing group 1), ERCC1 (excision cross-complementing gene) and GSTP1 (glutathione S-transferase) have a role in the development of pharmacoresistance to platinum derivatives. Platinum 179-187 glutathione S-transferase pi 1 Homo sapiens 89-94 17409936-1 2006 BACKGROUND: Polymorphisms within the P1 isoenzyme of GST (GSTP1) are associated with alterations in enzyme activity and may change sensitivity to platinum-based chemotherapy. Platinum 146-154 glutathione S-transferase pi 1 Homo sapiens 58-63 17409936-9 2006 CONCLUSIONS: GSTP1 haplotype can be used to stratify hematological toxicity after platinum-based chemotherapy, but the lack of significant associations with response or survival suggests that GSTP1 polymorphisms may not be strong pharmacogenomic markers in this population. Platinum 82-90 glutathione S-transferase pi 1 Homo sapiens 13-18 16342067-4 2006 In this study, the authors hypothesized that variant GSTP1 genotype would result in reduced inactivation of chemotherapy agents and improved survival in patients with advanced-stage nonsmall cell lung carcinoma (NSCLC), a population that is likely to receive platinum-based chemotherapy. Platinum 259-267 glutathione S-transferase pi 1 Homo sapiens 53-58 34347217-2 2022 In addition, glutathione S transferase (GST) P1 is involved in the metabolism of platinum agents. Platinum 81-89 glutathione S-transferase pi 1 Homo sapiens 13-47 34780261-1 2021 BACKGROUND: Genetic polymorphism within the P1 isoenzyme of the Glutathione-S-Transferase (GST) family is found to modulate and alter the enzyme activity of GSTP1 protein and thus may result in a change of sensitivity to platinum-based chemotherapy. Platinum 221-229 glutathione S-transferase pi 1 Homo sapiens 157-162 35455437-0 2022 Association between Genetic Polymorphism of GSTP1 and Toxicities in Patients Receiving Platinum-Based Chemotherapy: A Systematic Review and Meta-Analysis. Platinum 87-95 glutathione S-transferase pi 1 Homo sapiens 44-49 35455437-3 2022 Polymorphisms within the glutathione S-transferase pi 1 (GSTP1) gene may especially alter enzyme activity and, consequently, various toxicities in patients receiving platinum-based chemotherapy. Platinum 166-174 glutathione S-transferase pi 1 Homo sapiens 25-55 35455437-3 2022 Polymorphisms within the glutathione S-transferase pi 1 (GSTP1) gene may especially alter enzyme activity and, consequently, various toxicities in patients receiving platinum-based chemotherapy. Platinum 166-174 glutathione S-transferase pi 1 Homo sapiens 57-62 35455437-4 2022 Due to a lack of consistency in the degree of elevated complication risk, we performed a systematic literature review and meta-analysis to determine the level of platinum-associated toxicity in patients with the GSTP1 rs1695 polymorphism. Platinum 162-170 glutathione S-transferase pi 1 Homo sapiens 212-217 35455437-10 2022 Our study found that the GSTP1 rs1695 polymorphism was significantly correlated with platinum-induced toxicities. Platinum 85-93 glutathione S-transferase pi 1 Homo sapiens 25-30